Specific antibodies to Trypanosoma cruzi among blood donors in Los Angeles, California

Ia, Shulman; Appleman,; Saxena, S.N.; Al, Hiti; Lv, Kirchhoff

doi:10.1046/j.1537-2995.1997.37797369449.x

Cited by 48 publications

(37 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Over seven million people who originated from countries where Chagas' disease is endemic reside in the United States, and it is estimated that over 100,000 people are asymptomatically infected with T. cruzi in the United States and Canada (8,20). Screening of blood donors in Los Angeles County (California) has demonstrated T. cruzi seropositivity rates of 1 in 500 (22). However, screening of 100,019 blood donors in the southwestern United States identified only three donors who were repeatedly seropositive (10).…”

Section: Vol 47 2003 Inactivation Of T Cruzi In Platelets and Plasmentioning

confidence: 99%

“…To date, United States blood banks have not implemented screening for T. cruzi serologies. The immigration of Latin Americans into the United States ensures that there is a risk of transfusion infection with T. cruzi (6,(10)(11)(12)22). Indeed, at least six documented transfusion-associated T. cruzi infections have occurred in the United States and Canada (5,7,24), and probably many more undocumented transfusion-associated infections have occurred.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Trypanosoma cruziInactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV

Voorhis

Barrett²,

Eastman³

et al. 2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Trypanosoma cruzi, the protozoan pathogen that causes Chagas' disease, can be found in the blood of infected individuals for their entire life span. This presents a serious challenge in safeguarding blood products. Transmission of T. cruzi from blood products is a frequent occurrence in Latin America, where Chagas' disease is endemic. This study was designed to determine whether T. cruzi could be inactivated in human platelet concentrates and plasma by a photochemical treatment process with long-wavelength UV A light (UVA, 320 to 400 nm) plus the psoralen amotosalen HCl (Cerus Corporation). Units of platelet concentrates (300 ml) and plasma (300 ml) were intentionally contaminated with approximately 10 6 T. cruzi trypomastigotes, the T. cruzi form found in the bloodstream, per ml. The viability of T. cruzi after photochemical inactivation was determined by their ability to replicate in 3T3 fibroblasts. Controls, including treatment with 150 M amotosalen or 3 J/cm 2 UVA alone, did not lead to reduction of the viability of T. cruzi in plasma or platelet concentrates. However, treatment with 150 M amotosalen plus 3 J/cm 2 UVA inactivated T. cruzi to undetectable levels in plasma and platelet concentrates. This represented a >5.4-log reduction of T. cruzi in platelet concentrates and >5.0-log reduction of T. cruzi in plasma. We conclude that the amotosalen plus UVA photochemical inactivation technology is effective in inactivating high levels of protozoan pathogens, such as T. cruzi, in platelet concentrates and plasma, as has been previously shown for numerous viruses and bacteria.

show abstract

Section: Vol 47 2003 Inactivation Of T Cruzi In Platelets and Plasmentioning

confidence: 99%

mentioning

confidence: 99%

Trypanosoma cruziInactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV

Voorhis

Barrett²,

Eastman³

et al. 2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Due to the intense immigration from endemic areas, transfusion-related infection has recently been perceived as a potential threat in the USA 3 . Among its many manifestations, the cardiac involvement is very prominent, being both frequent and often disabling 4 .…”

Section: Introductionmentioning

confidence: 99%

Transplante de células da medula óssea na insuficiência cardíaca chagásica: relato da primeira experiência humana

Vilas-Boas¹,

Feitosa²,

Soares³

et al. 2011

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

“…3-5 Transmission via the placenta or by blood transfusion is the responsible mechanism for the occurrence of Chagas' disease in developed ctries where the disease is not endemic. 6,7 Toxoplasmosis is caused by Toxoplasma gondii, a complex eukaryotic parasite that has adopted an essential intracellular survival strategy. 5,8 Most of T.gondii infections are asymptomatic.…”

Section: Introductionmentioning

confidence: 99%

Fluorine-containing aryloxyethyl thiocyanate derivatives are potent inhibitors of Trypanosoma cruzi and Toxoplasma gondii proliferation

Liñares

Gismondi

Codesido

et al. 2007

Bioorganic & Medicinal Chemistry Letters

View full text Add to dashboard Cite

As a part of our project aimed at developing new safe chemotherapeutic and chemoprophylactic agents against tropical diseases, fluorine-containing drugs structurally related to 4-phenoxyphenoxyethyl thiocyanate (1) were designed, synthesized and evaluated as antiproliferative agents against Trypanosoma cruzi, the parasite responsible of American trypanosomiasis (Chagas' disease) and Toxoplasma gondii, the etiological agent of toxoplasmosis. This thiocyanate derivative had previously proven to be an effective agent against T. cruzi proliferation. Fluorine-containing ©2007 Elsevier Science Ltd. All rights reserved. *Corresponding author. Tel.: +54 11 4576 3346; fax: +54 11 4576-3385; e-mail: E-mail: jbr@qo.fcen.uba.ar . Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. It multiplies within the insect gut as an epimastigote form and is spread as a non-dividing metacyclic trypomastigote from the insect feces by contamination of intact mucosa or wounds produced by the blood-sucking activity of the vector. In the mammalian host, T. cruzi proliferates as the intracellular amastigote form, which is next released into the bloodstream as a non-dividing highly infective trypomastigote that can either invade other tissues or can infect the respective Chagas' disease vectors closing the cycle. 3-5 Transmission via the placenta or by blood transfusion is the responsible mechanism for the occurrence of Chagas' disease in developed ctries where the disease is not endemic. 6,7 NIH Public AccessToxoplasmosis is caused by Toxoplasma gondii, a complex eukaryotic parasite that has adopted an essential intracellular survival strategy. 5,8 Most of T.gondii infections are asymptomatic. There are two asexual forms that can cause disease in humans. The tachyzoite form, which can invade all types of cells and divides rapidly leading to cell death, and the bradyzoite form that divides slowly and forms cysts in muscle and brain. 9The existing chemotherapy either for Chagas' disease or for toxoplasmosis remains deficient. The chemotherapy for Chagas' disease is based on two drugs empirically discovered, nifurtimox, now discontinued, and benznidazole. Although both of these compounds are able to cure at least 50% of recent infections as indicated by the disappearance of symptoms, and reduction of parasitemia and serology, they present severe side effects. 10,11 The standard treatment against T. gondii infections consists in the combination of pyrimethamine, which inhibits the enzymatic activity of dihydrofolate reductase, and sulfadiazine, whose target is dihydropteroate synthetase. 12 This thera...

show abstract

Specific antibodies to Trypanosoma cruzi among blood donors in Los Angeles, California

Cited by 48 publications

References 15 publications

Trypanosoma cruziInactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV

Trypanosoma cruziInactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV

Transplante de células da medula óssea na insuficiência cardíaca chagásica: relato da primeira experiência humana

Fluorine-containing aryloxyethyl thiocyanate derivatives are potent inhibitors of Trypanosoma cruzi and Toxoplasma gondii proliferation

Contact Info

Product

Resources

About